7-5/2022/EU/WC-0532

Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA, Bhawan Kotla Road,
New Delhi-110002
Dated:

To

M/s SNA Healthcare Pvt. Ltd, N-213/3, M.I.D.C. Tarapur, 23 AUG 2022
Dist: Palghar, Boisar - 401506, Taluka:
MIDC Tarapur Boisar, District: Thane-Zone4
Maharashtra India

Subject:- Written Confirmation of M/s SNA Healthcare Pvt. Ltd, N-213/3, M.I.D.C. Tarapur, Dist: Palghar, Boisar - 401506, Taluka: MIDC Tarapur Boisar, District: Thane-Zone4 Maharashtra India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no WC/FR/2022/4706 submitted to CDSCO, West Zone office Mumbai and the recommendation received from DDC(I), West Zone Mumbai on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).

2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.

3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.

4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.

5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.

6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.

8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
---	02	23 AUG 2022	Three years from **date of issue**

Yours faithfully,

(Dr. V. G. Somani)
Drugs Controller **General (India)**

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

CERTIFICATE NO. : **WC-0532**

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: **M/s SNA Healthcare Pvt. Ltd, N-213/3, M.I.D.C. Tarapur, Dist: Palghar, Boisar - 401506, Taluka: MIDC Tarapur Boisar, District: Thane-Zone4 Maharashtra India**

2. Manufacturer's licence number: 25-KD/744

Regarding the manufacturing plant under (1) of the following Active substance(s) exported to the EU for medicinal products for human use

List of APIs as below and enclosed as annexure 1

S. No.	Active substance(s)	Activity(ies)
1.	Selenious Acid USP	Manufacturing & Packing
2.	Sodium Selenite Pentahydrate EP	Manufacturing & Packing

The issuing Regulatory Authority hereby confirms that:

The standards of good manufacturing practice applicable to this manufacturing plant are at least equivalent to those laid down in the EU (=GMP of WHO/ICH Q7);

The manufacturing plant is subject to regular, strict and transparent controls and to the effective enforcement of good manufacturing practice, including repeated and unannounced inspections, so as to ensure a protection of public health at least equivalent to that in the EU; and

In the event of findings relating to non-compliance, information on such findings is supplied by the exporting third country without delay to the EU.

Date of Inspection of the plant: 08.07.2021 & 09.07.2021

The Written Confirmation remains valid until: **Three years from date of issue**

The authenticity of this written confirmation may be verified with the issuing regulatory authority.

This written confirmation is without prejudice to the responsibilities of the manufacturer to ensure the quality of the medicinal product in accordance with Directive 2001/83/EC.

Address of the issuing regulatory authority: **Central Drugs Standard Control Organisation**
FDA Bhawan, Kotla Road,
New Delhi- 110 002, India

Name and function of responsible person: Dr. V. G. Somani
Drugs Controller General (India)

E-mail: dci@nic.in,
Telephone no.: +91-11-23236965
Fax no.: +91-11-23236973

23 AUG 2022

Signature

Stamp of the authority and date

Central Drugs Standard Control Organization
Ministry of Health & Family Welfare, Govt. of India

7-5/2022/EU/WC-0532

Government of India
Directorate General of Health Services
Central Drugs Standard Control Organisation
(International Cell)

FDA Bhawan, Kotla Road,
New Delhi-110002
Dated 15 MAY 2025

To

M/s. SNA Healthcare Pvt. Ltd.,
N-213/3, M.I.D.C. Tarapur, Dist. Palghar,
Boisar-401506 Thane-Zone 4, Maharashtra, India

SUB:- Written Confirmation of **M/s. SNA Healthcare Pvt. Ltd., N-213/3, M.I.D.C. Tarapur, Dist. Palghar, Boisar-401506 Thane-Zone 4, Maharashtra, India** as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-reg.

Sir,

Please refer to your online application no. WC/FR/2024/9143 submitted to DDC(I), CDSCO, West – Zone Mumbai Office, and the recommendation received from DDC(I), CDSCO, West – Zone Mumbai Office on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions: -

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).

2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.

3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.

4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.

5. The Written Confirmation will be withdrawn in the events of non-compliance of Standards.

6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non-Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.

8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

9. The manufacturer is required to comply with the provisions of GSR 20(E), dated 18.01.2022.

10. Policresulen IH and Cyclopentolate Hydrochloride USP have not been considered due to non-submission of satisfactory query response. Further, Selenious Acid USP and Sodium Selenite Pentahydrate EP are also not considered as you are already holding valid written confirmation certificate for the same.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
--	02	23.08.2022	**22.08.2025**
01	07	15 MAY 2025	**22.08.2025**

Yours faithfully,

15/05/25

Ranga Chandrashekar
Joint Drugs Controller (India)

चंद्रशेखर रंगा/Chandrashekar Ranga
संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller(India)
केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय
C.D.S.C.O(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
एफ.डी.ए भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002

GOVERNMENT OF INDIA
MINISTRY OF HEALTH & FAMILY WELFARE
Central Drugs Standard Control Organization

CERTIFICATE NO. : Annexure-01
WC-0532

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site: M/s. SNA Healthcare Pvt. Ltd.,
N-213/3, M.I.D.C. Tarapur, Dist. Palghar,
Boisar-401506 Thane-Zone 4, Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
01	ALLANTOIN USP	Manufacturing & Packing
02	BACLOFEN BP/USP	Manufacturing & Packing
03	EPERISONE HYDROCHLORIDE JP	Manufacturing & Packing
04	ETAMSYLATE BP/Ph.Eur.	Manufacturing & Packing
05	TOLPERISONE HYDROCHLORIDE JP	Manufacturing & Packing
06	TROPICAMIDE USP	Manufacturing & Packing
07	HYDROUS BENZOYL PEROXIDE BP/USP	Manufacturing & Packing

ITEM(S) SEVEN (07) ONLY

The Written Confirmation remains valid until: 22.08.2025.

Chandrashekar 15/05/25

Signature

चंद्रशेखर रंगा/Chandrashekar Ranga
संयुक्त औषधि नियंत्रक (भारत) / Joint Drugs Controller(India)
केंद्रीय औषधि मानक नियंत्रण संगठन (मुख्यालय), स्वास्थ्य सेवा महानिदेशालय
C.D.S.C.O(HQ), Dte. General of Health Services
स्वास्थ्य और परिवार कल्याण मंत्रालय / Ministry of Health and Family Welfare
एफ.डी.ए भवन, कोटला रोड, नई दिल्ली-110002 / FDA Bhawan, Kotla Road, New Delhi-110002

Stamp of the authority and date

Central Drugs Standard Control Organisation * Ministry of Health & Family Welfare, Govt. of India * सत्यमेव जयते

15 MAY 2025